Search
Bicycle Therapeutics PLC
BCYCAdd to Watchlist
3.990USD
+0.090+2.31%
Market hours （ET）Quotes delayed by 15 min
200.57MMarket Cap
LossP/E TTM
Forecast
Currency: USD Updated: 2026-08-14The current earnings forecast score of Bicycle Therapeutics PLC is 8.00, ranking 170 out of 387 in the Biotechnology & Medical Research industry. The average price target is 16.00, with a high of 44.00 and a low of 6.00.
Analyst Rating
Based on
10
analysts
Buy
Current Rating
10.143
Target Price
+160.07%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
497
Total
6
Median
7
Average
Company name
Ratings
Analysts
Bicycle Therapeutics PLC
BCYC
10
Beigene Ltd
ONC
28
argenx SE
ARGX
28
Ionis Pharmaceuticals Inc
IONS
25
IQVIA Holdings Inc
IQV
24
Kymera Therapeutics Inc
KYMR
23
1
2
3
...
100
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Bicycle Therapeutics PLC's expected revenue for the next quarter?
Bicycle Therapeutics PLC's expected revenue is 2.35M.
What is Bicycle Therapeutics PLC's price target?
Analysts forecast that Bicycle Therapeutics PLC's price target is USD 16.00, with the highest forecast at USD 44.00 and the lowest forecast at USD 6.00.
How have Bicycle Therapeutics PLCBCYC's recent earnings per share performed?
The market expectation was USD -0.72, while Bicycle Therapeutics PLCBCYC's earnings per share (EPS) for the previous quarter was USD -0.87. EPS for the next quarter is expected at USD -0.46.
What is the analyst rating for Bicycle Therapeutics PLC?
Based on the ratings of Bicycle Therapeutics PLC's stock from 10 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.